From the Research
Rheumasser from GL Pharma should be used as part of a comprehensive treatment plan for rheumatoid arthritis, with methotrexate as the first-line antirheumatic drug, and considering combination therapy with other disease-modifying antirheumatic drugs (DMARDs) or biologic drugs for patients with inadequate response to methotrexate monotherapy, as supported by the most recent and highest quality study 1. The treatment of rheumatoid arthritis involves a range of options, including methotrexate, sulfasalazine, hydroxychloroquine, and biologic drugs such as etanercept and adalimumab.
- Key considerations for treatment include:
- Methotrexate as the first-line antirheumatic drug, due to its well-established efficacy and safety profile 2
- Combination therapy with other DMARDs or biologic drugs for patients with inadequate response to methotrexate monotherapy, as shown to be effective in several studies 3, 4, 1, 5
- Monitoring for adverse effects and adjusting treatment as needed to minimize risks and optimize outcomes The most recent and highest quality study 1 provides strong evidence for the effectiveness of combination therapy with methotrexate and other DMARDs or biologic drugs, and should be considered as the primary guide for treatment decisions.
- Important factors to consider when selecting a treatment regimen include:
- Patient-specific factors, such as disease severity, medical history, and preferences
- The potential benefits and risks of each treatment option, including the risk of adverse effects and the potential for improved outcomes
- The need for ongoing monitoring and adjustment of treatment to ensure optimal outcomes and minimize risks.